摘要
目的 分析放化疗联合细胞免疫治疗广泛期小细胞肺癌的临床疗效。方法 我院2022年3月至2023年收治的广泛期小细胞肺癌患者100例，随机分为对照组（49例）和实验组（51例），对照组采用常规放化疗，实验组采用广泛期小细胞肺癌化疗联合细胞免疫治疗，比较两组患者行为能力评分（ Karnofsky ，KPS）评分、中位生存期、1年生存率。结果 治疗前，两组患者KPS评分比较差异无统计学意义（P>0.05），治疗后，实验组KPS评分明显高于对照组（P<0.05）；实验组中位生存期、1年生存率均明显高于对照组（P<0.05）。结论 放化疗联合治疗广泛期小细胞肺癌可有效改善广泛期小细胞肺癌患者的KPS评分，提高中位生存期及1年生存率，值得推广。
关键词： 广泛性小细胞肺癌放化疗；细胞免疫；临床疗效及用药依从性
Abstract
Objective To analyze the clinical efficacy of chemoradiotherapy combined with cell immunotherapy in extensive stage small cell lung cancer. Methods from March 2022 to 2023, a total of 100 cases were randomized into the control group (n=49) and experimental group (n=51), the control group used conventional chemoradiotherapy, the experimental group with extensive small cell lung cancer chemotherapy combined with cell immunotherapy, comparing the two groups of behavioral ability (Karnofsky, KPS) score, median survival, and 1-year survival rate. Results Before treatment, there was no significant difference in KPS scores between the two groups (P> 0.05), and after treatment, the KPS score of the experimental group was significantly higher than that of the control group (P <0.05); the median survival and 1-year survival rate of the experimental group were significantly higher than that of the control group (P <0.05). Conclusion Radiation and chemotherapy combined with extensive stage small cell lung cancer effectively improves the KPS score of patients with extensive stage small cell lung cancer, and improves the median survival period and 1-year survival rate, which is worth popularizing.
Key words： Radiotherapy and chemotherapy for extensive small cell lung cancer, cellular immunity, clinical efficacy and medication compliance
参考文献 References
[1] Wang Mengjuan, Kong Tiantian, Li Hongyu, Liu Chaoying. Clinical effect of duvalizumab plus chemotherapy for extensive stage small cell lung cancer [J]. Chinese Journal of Gerontology, 2023, 43 (23): 5676-5679.
[2] Li Jianguo, Li Shuman, Chen Hui. Efficacy and safety of anlotinib combined with PD-1 inhibitor in broad-stage small cell lung cancer [J]. Journal of Practical Medicine, 2023, 39 (17): 2248-2252.
[3] Jing Yawan, Zeng Hao, Cheng Ruixin, Tian Panwen, Li Yarun. Mechanism of immunoresistance and coping strategies in non-small cell lung cancer [J]. Chinese Journal of Lung Cancer, 2023, 26 (1): 66-77.
[4] Zhang Xiaohan, Zhu Wentao, Ju Wenxiang, Zhao Yingying, Lu Luolan, Shen Aizong. Cost-effectiveness analysis of adliberlizumab plus first-line chemotherapy for broad-stage small cell lung cancer [J]. Chinese Journal of Hospital Pharmacy, 2023, 43 (22): 2545-2550.
[5] He Hua, Hu Wenteng, Ma Minjie, Han Biao. Systematic evaluation of efficacy and Meta-analysis of surgical resection and concurrent chemoradiotherapy in A-N2 stage non-small cell lung cancer after induction chemotherapy or chemoradiotherapy [J]. Chinese Clinical Journal of Thoracic and Cardiovascular Surgery, 2023, 30 (1): 133-139.
[6] Min Xuhong, Wang Shanghu, Sheng Lei, Song Biao, Wang Mengjie, Li Yun, Shi Shanshan, Ma Dongchun. Clinical analysis of carlizumab combined with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer [J]. Chinese Journal of Cancer Prevention and Treatment, 2023, 30 (10): 600-605.